JNJ vs PFE
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | JNJ | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-09 close | $261.44 | $28.28 | |
| Market cap | $630.0B | $161.2B | |
| P/E as of 2026-10-09 | 30.31 | 37.44 | JNJ lower |
| Net margin FY2025, SEC XBRL | +28.5% | +12.4% | JNJ higher |
| Gross margin FY2025, SEC XBRL | +67.9% | n/a | |
| ROE FY2025, SEC XBRL | +32.9% | +9.0% | JNJ higher |
| ROA FY2025, SEC XBRL | +13.5% | +3.7% | JNJ higher |
| Debt / equity as of 2026-09-02 | 0.58 | 0.74 | JNJ lower |
| Revenue growth (YoY) as of 2026-09-02 | +8.1% | -0.2% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | -14.8% | JNJ higher |
| Dividend yield as of 2026-09-02 | +2.0% | +6.2% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 5 | 11 | PFE higher |
| Beta as of 2026-09-02 | -0.02 | 0.39 | |
| 1-year return as of 2026-10-09 close | +36.8% | +12.0% | JNJ higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.